| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Real-Time Polymerase Chain Reaction | 5 | 2014 | 299 | 0.970 |
Why?
|
| beta-Lactamases | 3 | 2013 | 57 | 0.810 |
Why?
|
| Polymerase Chain Reaction | 10 | 2020 | 930 | 0.780 |
Why?
|
| DNA Primers | 5 | 2011 | 548 | 0.450 |
Why?
|
| Bacteriological Techniques | 2 | 2012 | 40 | 0.440 |
Why?
|
| Klebsiella Infections | 2 | 2012 | 32 | 0.430 |
Why?
|
| Klebsiella pneumoniae | 2 | 2012 | 41 | 0.430 |
Why?
|
| Pancreatic Neoplasms | 8 | 2024 | 725 | 0.410 |
Why?
|
| Anal Canal | 1 | 2013 | 92 | 0.380 |
Why?
|
| Neonatal Sepsis | 2 | 2023 | 6 | 0.380 |
Why?
|
| Transforming Growth Factor beta | 4 | 2024 | 349 | 0.360 |
Why?
|
| Mutation | 7 | 2024 | 4374 | 0.340 |
Why?
|
| Bacteria | 2 | 2023 | 517 | 0.340 |
Why?
|
| Adenoviridae | 3 | 2024 | 342 | 0.330 |
Why?
|
| DNA, Bacterial | 4 | 2020 | 253 | 0.320 |
Why?
|
| Oncolytic Virotherapy | 2 | 2020 | 43 | 0.310 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2009 | 46 | 0.310 |
Why?
|
| BRCA2 Protein | 1 | 2009 | 175 | 0.290 |
Why?
|
| BRCA1 Protein | 1 | 2009 | 216 | 0.280 |
Why?
|
| RNA, Viral | 3 | 2025 | 311 | 0.280 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2007 | 17 | 0.260 |
Why?
|
| Placenta | 2 | 2025 | 191 | 0.250 |
Why?
|
| Plasmodium | 1 | 2005 | 11 | 0.230 |
Why?
|
| Malaria | 1 | 2005 | 26 | 0.230 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2010 | 115 | 0.230 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2024 | 94 | 0.220 |
Why?
|
| Abortion, Spontaneous | 1 | 2025 | 74 | 0.220 |
Why?
|
| Adenocarcinoma | 4 | 2024 | 1215 | 0.220 |
Why?
|
| Fetus | 1 | 2025 | 239 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 127 | 0.210 |
Why?
|
| Adenoviridae Infections | 1 | 2024 | 16 | 0.210 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2024 | 58 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 76 | 0.200 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 319 | 0.180 |
Why?
|
| Genes, ras | 5 | 1995 | 97 | 0.180 |
Why?
|
| Sepsis | 2 | 2023 | 391 | 0.180 |
Why?
|
| Genetic Vectors | 2 | 2020 | 446 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 190 | 0.170 |
Why?
|
| ROC Curve | 2 | 2021 | 797 | 0.170 |
Why?
|
| Fetal Blood | 1 | 2021 | 96 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 540 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2020 | 9 | 0.160 |
Why?
|
| Humans | 32 | 2025 | 96108 | 0.160 |
Why?
|
| Oncolytic Viruses | 1 | 2019 | 24 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2018 | 143 | 0.150 |
Why?
|
| Tuberculosis | 1 | 2020 | 125 | 0.140 |
Why?
|
| Immunity | 1 | 2019 | 157 | 0.140 |
Why?
|
| Liver | 3 | 2025 | 1238 | 0.140 |
Why?
|
| Pancreatic Ducts | 2 | 1994 | 30 | 0.130 |
Why?
|
| Staphylococcal Infections | 2 | 2014 | 289 | 0.130 |
Why?
|
| Influenza, Human | 2 | 2010 | 370 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 591 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 2039 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1670 | 0.110 |
Why?
|
| Prevalence | 2 | 2023 | 1349 | 0.110 |
Why?
|
| Point Mutation | 2 | 2013 | 247 | 0.110 |
Why?
|
| Base Sequence | 6 | 2007 | 2344 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2006 | 279 | 0.110 |
Why?
|
| Autopsy | 2 | 2025 | 129 | 0.110 |
Why?
|
| Formaldehyde | 2 | 2013 | 53 | 0.100 |
Why?
|
| Paraffin Embedding | 2 | 2013 | 79 | 0.100 |
Why?
|
| Pancreatectomy | 1 | 2014 | 168 | 0.100 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2013 | 5 | 0.100 |
Why?
|
| Clarithromycin | 1 | 2013 | 7 | 0.100 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 43 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 85 | 0.100 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 1798 | 0.100 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 43 | 0.100 |
Why?
|
| Helicobacter Infections | 1 | 2013 | 38 | 0.100 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 38 | 0.100 |
Why?
|
| Long-Term Care | 1 | 2013 | 63 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1995 | 465 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 106 | 0.100 |
Why?
|
| Nucleic Acids | 1 | 2013 | 36 | 0.100 |
Why?
|
| Gastritis | 1 | 2013 | 39 | 0.100 |
Why?
|
| Oncogenes | 2 | 1995 | 100 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2006 | 477 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 84 | 0.090 |
Why?
|
| Thyroidectomy | 1 | 2013 | 173 | 0.090 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 136 | 0.090 |
Why?
|
| Stomach | 1 | 2013 | 115 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 547 | 0.090 |
Why?
|
| Culture Media | 1 | 2012 | 150 | 0.090 |
Why?
|
| Adenoma, Islet Cell | 1 | 1992 | 28 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 793 | 0.090 |
Why?
|
| Rodentia | 1 | 1992 | 47 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 287 | 0.090 |
Why?
|
| Adult | 9 | 2025 | 28722 | 0.080 |
Why?
|
| Virology | 1 | 2010 | 13 | 0.080 |
Why?
|
| Female | 12 | 2025 | 50030 | 0.080 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 14 | 0.080 |
Why?
|
| Robotics | 1 | 2013 | 273 | 0.080 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2010 | 87 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 74 | 0.080 |
Why?
|
| Neoplasms | 2 | 2022 | 3248 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2023 | 10287 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 2778 | 0.080 |
Why?
|
| Prostatectomy | 1 | 2013 | 480 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 1069 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2010 | 177 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7229 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2023 | 2614 | 0.070 |
Why?
|
| Genes, BRCA2 | 1 | 2009 | 162 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2009 | 192 | 0.070 |
Why?
|
| Middle Aged | 9 | 2024 | 28369 | 0.070 |
Why?
|
| Animals | 11 | 2024 | 28891 | 0.070 |
Why?
|
| Species Specificity | 2 | 2007 | 707 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 528 | 0.070 |
Why?
|
| Cytokines | 2 | 2024 | 871 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 847 | 0.070 |
Why?
|
| DNA | 2 | 2009 | 1333 | 0.070 |
Why?
|
| Chlamydophila psittaci | 1 | 2007 | 2 | 0.070 |
Why?
|
| Eye Neoplasms | 1 | 2007 | 25 | 0.070 |
Why?
|
| Male | 12 | 2024 | 45865 | 0.060 |
Why?
|
| Pregnancy | 2 | 2025 | 3240 | 0.060 |
Why?
|
| Chlamydia Infections | 1 | 2007 | 32 | 0.060 |
Why?
|
| Aged | 7 | 2024 | 20968 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3157 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2013 | 784 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 52 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 922 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 829 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1773 | 0.060 |
Why?
|
| Staphylococcus | 1 | 2005 | 24 | 0.060 |
Why?
|
| DNA, Protozoan | 1 | 2005 | 15 | 0.060 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2005 | 34 | 0.060 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 28 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 3040 | 0.060 |
Why?
|
| Cell Line | 1 | 2009 | 2537 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 1805 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2007 | 271 | 0.050 |
Why?
|
| Genes, p53 | 2 | 1995 | 109 | 0.050 |
Why?
|
| Mice | 5 | 2024 | 12537 | 0.050 |
Why?
|
| Cell Communication | 1 | 2005 | 221 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 883 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2005 | 329 | 0.050 |
Why?
|
| Mesocricetus | 5 | 1995 | 103 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 1995 | 166 | 0.050 |
Why?
|
| Cricetinae | 5 | 1995 | 542 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2024 | 3581 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 180 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 897 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 48 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2021 | 41 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 465 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1957 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 272 | 0.040 |
Why?
|
| Hospitals | 2 | 2013 | 329 | 0.040 |
Why?
|
| Carcinogens | 3 | 1995 | 106 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 64 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2007 | 175 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 162 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 145 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2019 | 156 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2534 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2882 | 0.040 |
Why?
|
| Lung | 1 | 2025 | 1384 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1049 | 0.040 |
Why?
|
| Gene Expression | 2 | 1994 | 1320 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 830 | 0.040 |
Why?
|
| Methylnitrosourea | 2 | 1994 | 7 | 0.030 |
Why?
|
| Virus Replication | 1 | 2019 | 326 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 188 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 101 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1063 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 290 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 880 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 225 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 403 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 4028 | 0.030 |
Why?
|
| Cell Aggregation | 2 | 2006 | 39 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1992 | 1346 | 0.030 |
Why?
|
| Culture Media, Conditioned | 2 | 2006 | 103 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 21 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2009 | 910 | 0.030 |
Why?
|
| Nitrosourea Compounds | 1 | 1994 | 9 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 67 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 80 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 50 | 0.030 |
Why?
|
| Child | 2 | 2020 | 7626 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 5580 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 7026 | 0.030 |
Why?
|
| Fixatives | 1 | 2013 | 12 | 0.030 |
Why?
|
| Exons | 2 | 1995 | 454 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2013 | 54 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2013 | 40 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 9896 | 0.020 |
Why?
|
| Kallikreins | 1 | 2013 | 46 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 89 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2013 | 72 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 908 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2010 | 3974 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 153 | 0.020 |
Why?
|
| Chromogenic Compounds | 1 | 2012 | 5 | 0.020 |
Why?
|
| Agar | 1 | 2012 | 9 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2013 | 109 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1535 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 901 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1196 | 0.020 |
Why?
|
| Illinois | 1 | 2013 | 531 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 1992 | 186 | 0.020 |
Why?
|
| Rectum | 1 | 2012 | 151 | 0.020 |
Why?
|
| Trout | 1 | 1991 | 2 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 1992 | 206 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 346 | 0.020 |
Why?
|
| General Surgery | 1 | 2013 | 255 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 1995 | 750 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2009 | 51 | 0.020 |
Why?
|
| Introns | 1 | 1991 | 304 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1990 | 126 | 0.020 |
Why?
|
| Adenoma | 1 | 1992 | 260 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 1220 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1994 | 2939 | 0.020 |
Why?
|
| Nitrosamines | 3 | 1995 | 9 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1828 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 3110 | 0.020 |
Why?
|
| Chicago | 1 | 2012 | 1506 | 0.020 |
Why?
|
| Mass Screening | 1 | 2012 | 710 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2090 | 0.020 |
Why?
|
| Chemotactic Factors | 1 | 2005 | 13 | 0.010 |
Why?
|
| Transition Temperature | 1 | 2005 | 10 | 0.010 |
Why?
|
| DNA Probes | 1 | 2005 | 77 | 0.010 |
Why?
|
| Blood | 1 | 2005 | 69 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 172 | 0.010 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2005 | 101 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2005 | 259 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 705 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 306 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 3363 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 354 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 816 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1995 | 34 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 394 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 422 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 648 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1995 | 358 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1992 | 149 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1995 | 684 | 0.010 |
Why?
|